Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma

Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN).

(2017) K. J. Harrington et al.   JOURNAL OF CLINICAL ONCOLOGY

p16 protein status and response to treatment in a prospective clinical trial (ECOG 2303) of patients with head and neck squamous cell carcinoma (HNSCC).

(2017) A. Psyrri et al.   JOURNAL OF CLINICAL ONCOLOGY

Human papillomavirus (HPV)–related head and neck squamous cell carcinoma (HNSCC) and outcome after treatment with epidermal growth factor receptor inhibitors (EGFR inhib) plus radiotherapy (RT) versus conventional chemotherapy (CT) plus RT.

(2017) B. Pajares et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

(2017) L. L. Siu et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

(2012) J. A. de Souza et al.   CLINICAL CANCER RESEARCH

Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck

(2011) J M del Campo et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2011

(2011) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

(2011) Toni M. Brand et al.   CANCER BIOLOGY & THERAPY

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

(2011) P. A. Janne et al.   CLINICAL CANCER RESEARCH

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

(2011) Jean-Pascal Machiels et al.   LANCET ONCOLOGY

Epithelial–mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells

(2011) Carmen Holz et al.   RADIOTHERAPY AND ONCOLOGY

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

(2011) K. Yonesaka et al.   Science Translational Medicine

The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

(2011) Nicole G Chau et al.   Head and Neck Optical Diagnostics Society

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

(2010) L. Licitra et al.   ANNALS OF ONCOLOGY

Optimal treatment for recurrent/metastatic head and neck cancer

(2010) J. B. Vermorken et al.   ANNALS OF ONCOLOGY

New Strategies in Head and Neck Cancer: Understanding Resistance to Epidermal Growth Factor Receptor Inhibitors

(2010) L. F. Chen et al.   CLINICAL CANCER RESEARCH

Tyrosine Kinase Receptor Transactivation Associated to G Protein-Coupled Receptors

(2010) Vanessa Almendro et al.   CURRENT DRUG TARGETS

Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer

(2010) Angela Hong et al.   EUROPEAN JOURNAL OF CANCER

Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: Reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma

(2010) Chad E. Galer et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Integrating Epidermal Growth Factor Receptor Assay With Clinical Parameters Improves Risk Classification for Relapse and Survival in Head-and-Neck Squamous Cell Carcinoma

(2010) Christine H. Chung et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

(2010) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Should Cetuximab Replace Cisplatin in Head and Neck Cancer?

(2010) K. Rowan   JNCI-Journal of the National Cancer Institute

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

(2010) K. Kian Ang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity

(2010) D Basu et al.   ONCOGENE

Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation

(2010) S E Wheeler et al.   ONCOGENE

Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma

(2010) Kondo   ONCOLOGY REPORTS

Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse

(2010) Ira Skvortsova et al.   RADIOTHERAPY AND ONCOLOGY

Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium

(2009) M. Hashibe et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy

(2009) E. Martinelli et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Resistance to EGF-R (erbB-1) and VEGF-R modulating agents

(2009) Wolfram C.M. Dempke et al.   EUROPEAN JOURNAL OF CANCER

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

(2009) J. Simon W. Stewart et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of HPV-Associated p16INK4A Expression on Response to Radiotherapy and Survival in Squamous Cell Carcinoma of the Head and Neck

(2009) Pernille Lassen et al.   JOURNAL OF CLINICAL ONCOLOGY

Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells

(2009) Barry Jutten et al.   RADIOTHERAPY AND ONCOLOGY

Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma

(2008) Daniel T. T. Chua et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Chemoselection As a Strategy for Organ Preservation in Advanced Oropharynx Cancer: Response and Survival Positively Associated With HPV16 Copy Number

(2008) Francis P. Worden et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR, p16, HPV Titer, Bcl-xL and p53, Sex, and Smoking As Indicators of Response to Therapy and Survival in Oropharyngeal Cancer

(2008) Bhavna Kumar et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial

(2008) C. Fakhry et al.   JNCI-Journal of the National Cancer Institute

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

(2008) D L Wheeler et al.   ONCOGENE

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE